Genentech (NYSE:DNA) formerly known as (NYSE:GNE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

DNA 11.30

-2.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	10/10/2005 5:41:48 PM
	Read Replies (2) of 250

Avastin penetration in colorectal cancer: 3Q05 penetration in 2nd/3rd-line : 40% 2nd/3rd-line penetration range in past four quarters: 35-47% In 3Q05, the penetration rate increased Q-o-Q in the second line and was flat Q-o-Q in the third line. However, DNA does not break out these numbers. 3Q05 penetration in 1st-line mCRC was 67%, up from 64% in previous quarter. [Source: DNA CC in progress.]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next